Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 12 studies | 27% ± 10% | |
| smooth muscle cell | 9 studies | 24% ± 7% | |
| type I pneumocyte | 9 studies | 32% ± 12% | |
| pericyte | 8 studies | 22% ± 8% | |
| myofibroblast cell | 6 studies | 28% ± 7% | |
| adipocyte | 5 studies | 24% ± 8% | |
| adventitial cell | 4 studies | 26% ± 12% | |
| astrocyte | 4 studies | 25% ± 6% | |
| extravillous trophoblast | 3 studies | 87% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| placenta | 3 studies | 36% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 7650.87 | 244 / 245 | 94% | 24.87 | 473 / 502 |
| lung | 100% | 13356.49 | 578 / 578 | 88% | 42.19 | 1012 / 1155 |
| thymus | 97% | 3908.66 | 631 / 653 | 86% | 48.48 | 523 / 605 |
| breast | 98% | 6280.47 | 452 / 459 | 85% | 28.43 | 945 / 1118 |
| adrenal gland | 100% | 14412.69 | 258 / 258 | 83% | 52.07 | 190 / 230 |
| kidney | 90% | 4011.91 | 80 / 89 | 92% | 92.77 | 831 / 901 |
| uterus | 98% | 5311.74 | 167 / 170 | 76% | 39.88 | 348 / 459 |
| bladder | 95% | 7030.95 | 20 / 21 | 76% | 44.37 | 385 / 504 |
| skin | 86% | 4055.38 | 1556 / 1809 | 84% | 39.67 | 396 / 472 |
| intestine | 86% | 5506.74 | 832 / 966 | 80% | 33.56 | 420 / 527 |
| pancreas | 67% | 2649.79 | 220 / 328 | 96% | 116.11 | 170 / 178 |
| ovary | 99% | 5830.08 | 179 / 180 | 63% | 15.28 | 270 / 430 |
| esophagus | 83% | 5782.75 | 1205 / 1445 | 75% | 34.79 | 137 / 183 |
| stomach | 70% | 3391.12 | 252 / 359 | 77% | 29.72 | 219 / 286 |
| eye | 0% | 0 | 0 / 0 | 100% | 52.96 | 80 / 80 |
| ureter | 0% | 0 | 0 / 0 | 100% | 42.68 | 1 / 1 |
| blood vessel | 100% | 11775.84 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 7975.62 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| heart | 97% | 8031.09 | 839 / 861 | 0% | 0 | 0 / 0 |
| brain | 21% | 402.21 | 562 / 2642 | 62% | 13.15 | 437 / 705 |
| liver | 26% | 833.63 | 59 / 226 | 57% | 37.82 | 232 / 406 |
| spleen | 76% | 1918.83 | 182 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 47% | 30.69 | 21 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 31% | 7.63 | 9 / 29 |
| muscle | 6% | 131.79 | 48 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 5% | 123.42 | 43 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0002244 | Biological process | hematopoietic progenitor cell differentiation |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0030510 | Biological process | regulation of BMP signaling pathway |
| GO_0007275 | Biological process | multicellular organism development |
| GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
| GO_0032926 | Biological process | negative regulation of activin receptor signaling pathway |
| GO_0090101 | Biological process | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway |
| GO_0030154 | Biological process | cell differentiation |
| GO_0001503 | Biological process | ossification |
| GO_0022409 | Biological process | positive regulation of cell-cell adhesion |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0045671 | Biological process | negative regulation of osteoclast differentiation |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0005634 | Cellular component | nucleus |
| GO_0001968 | Molecular function | fibronectin binding |
| GO_0048185 | Molecular function | activin binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FSTL3 |
| Protein name | Follistatin-related protein 3 (Follistatin-like protein 3) (Follistatin-related gene protein) Follistatin like 3 |
| Synonyms | FLRG UNQ674/PRO1308 |
| Description | FUNCTION: Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such us activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiationc. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10. . |
| Accessions | A0A087WTD3 ENST00000591573.1 ENST00000605925.3 ENST00000588773.5 K7EM71 ENST00000166139.9 [O95633-1] O95633 A0A087X1Q2 ENST00000592947.5 ENST00000589185.2 |